Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death.
Neurodegenerative disorders are marked by extensive neuronal apoptosis and gliosis. Although several apoptosis-inducing agents have been described, understanding of the regulatory mechanisms underlying modes of cell death is incomplete. A major breakthrough in delineation of the mechanism of cell death came from elucidation of the sphingomyelin (SM)-ceramide pathway that has received worldwide attention in recent years. The SM pathway induces apoptosis, differentiation, proliferation, and growth arrest depending upon cell and receptor types, and on downstream targets. Sphingomyelin, a plasma membrane constituent, is abundant in mammalian nervous system, and ceramide, its primary catabolic product released by activation of either neutral or acidic sphingomyelinase, serves as a potential lipid second messenger or mediator molecule modulating diverse cellular signaling pathways. Neutral sphingomyelinase (NSMase) is a key enzyme in the regulated activation of the SM cycle and is particularly sensitive to oxidative stress. In a context of increasing clarification of the mechanisms of neurodegeneration, we thought that it would be useful to review details of recent findings that we and others have made concerning different pro-apoptotic neurotoxins including proinflammatory cytokines, hypoxia-induced SM hydrolysis and ceramide production that induce cell death in human primary neurons and primary oligodendrocytes: redox sensitive events. What has and is emerging is a vista of therapeutically important ceramide regulation affecting a variety of different neurodegenerative and neuroinflammatory disorders.
Jana
Arundhati
A
Department of Neurological sciences, Rush University Medical Center, Chicago, IL 60612, USA.
Hogan
Edward L
EL
Pahan
Kalipada
K
D000375:Aging / Q000502:physiology; D017209:Apoptosis / Q000187:drug effects; D002454:Cell Differentiation; D002518:Ceramides / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D021962:Membrane Microdomains / Q000378:metabolism; D008928:Mitochondria / Q000502:physiology; D009410:Nerve Degeneration / Q000503:physiopathology*; D009422:Nervous System Diseases / Q000503:physiopathology*; D019636:Neurodegenerative Diseases / Q000503:physiopathology*; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009498:Neurotoxins / Q000378:metabolism; D009836:Oligodendroglia / Q000187:drug effects / Q000502:physiology*; D018384:Oxidative Stress; D015398:Signal Transduction; D013109:Sphingomyelins / Q000378:metabolism
D002518:Ceramides; D016207:Cytokines; D009498:Neurotoxins; D013109:Sphingomyelins